Financial Performance - The company's operating revenue for 2024 was ¥445,864,331.31, a decrease of 32.75% compared to ¥663,025,874.35 in 2023[22]. - The net profit attributable to shareholders for 2024 was ¥91,547,379.78, down 48.02% from ¥176,116,201.67 in 2023[22]. - The basic earnings per share for 2024 was ¥0.32, a decline of 47.54% from ¥0.61 in 2023[22]. - The total assets at the end of 2024 were ¥2,488,655,694.01, a decrease of 2.27% from ¥2,546,570,975.79 at the end of 2023[22]. - The company reported a cash flow from operating activities of ¥96,073,242.89 in 2024, down 29.91% from ¥137,063,475.71 in 2023[22]. - The company’s net profit after deducting non-recurring gains and losses for 2024 was ¥72,955,012.10, a decrease of 57.14% from ¥170,236,321.77 in 2023[22]. - The weighted average return on equity for 2024 was 4.00%, down from 7.63% in 2023, a decline of 3.63%[22]. - The revenue from raw materials is ¥356,155,439.93, accounting for 79.88% of total revenue, down 35.78% from ¥554,613,468.87 in 2023[54]. - The revenue from formulations is ¥85,214,019.75, representing 19.11% of total revenue, a decrease of 17.57% from ¥103,376,153.77 in 2023[54]. - The gross margin for raw materials is 21.18%, down 14.92% year-on-year, while the gross margin for formulations is 59.48%, down 3.20% year-on-year[56]. Dividend Distribution - The company plans to distribute a cash dividend of 2.5 RMB per 10 shares to all shareholders, based on a total of 288 million shares[5]. - The board of directors has approved a profit distribution plan, with no bonus shares being issued[5]. - The company distributed a cash dividend of RMB 4.80 per 10 shares, totaling RMB 138,240,000.00, based on a total share capital of 288,000,000 shares[152]. Research and Development - R&D investment for the period was CNY 32,937,088.26, a decline of 37.59% compared to the previous year[44]. - The company is actively researching and developing various specialty APIs, including anti-tumor and cardiovascular drugs, to enrich its product line[47]. - The company has developed a series of ibuprofen derivative products to meet diverse customer needs and expand market reach[46]. - The company is in the trial production phase for new processes of R-enantiomer Ibuprofen, aiming to optimize production costs and enhance product competitiveness[66]. - Research and development (R&D) expenditure amounted to ¥32,937,088.26 in 2024, representing 7.39% of operating revenue, down from 7.96% in 2023[68]. Market and Product Development - The company focuses on the research, production, and sales of chemical raw materials and formulations, including non-steroidal anti-inflammatory drugs, cardiovascular drugs, and anti-tumor drugs[38]. - The company has established a contract development and manufacturing organization (CDMO) service to meet customer needs from preclinical to commercialization stages[38]. - The company is developing new products such as Torasemide injection and non-fluorobenzene tablets to enrich its product portfolio[67]. - The company aims to establish a global manufacturing base for ibuprofen and its derivatives, enhancing production capacity and product competitiveness[92]. - The company plans to develop a "specialty raw material drug manufacturing base" focusing on cardiovascular, anti-tumor, and anticholinergic drugs[92]. Environmental and Regulatory Compliance - The company has obtained multiple environmental protection approvals for various projects, including a 5,000-ton ibuprofen raw material project approved in July 2020[165]. - The company holds a valid pollution discharge permit, effective from December 28, 2020, to December 27, 2025[169]. - The company has received environmental impact report approvals for projects involving 1,200 tons of raw materials and 12 tons of anti-tumor raw materials in August 2024[168]. - The company has implemented necessary internal control measures to ensure compliance with national laws and regulations, preventing significant losses[160]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[188]. Corporate Governance - The company held 4 shareholder meetings during the reporting period, ensuring compliance with legal regulations and providing equal rights to all shareholders[106]. - The board of directors consists of 8 members, including 3 independent directors, and held 7 meetings during the reporting period, adhering to relevant laws and regulations[108]. - The supervisory board, comprising 3 members, conducted 6 meetings in accordance with legal requirements, effectively overseeing the company's operations and financial status[110]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations, with no instances of fund occupation or guarantees provided to the controlling shareholder[113]. - The company is committed to maintaining high standards of corporate governance with the appointment of qualified independent directors[128]. Management and Personnel - The total number of employees at the end of the reporting period is 987, with 872 from the parent company and 115 from major subsidiaries[148]. - The employee composition includes 663 production personnel, 20 sales personnel, 147 technical personnel, 19 financial personnel, and 138 administrative personnel[149]. - The company has implemented a competitive and fair salary policy, regularly adjusting salaries based on company performance and market surveys[150]. - The company has a diverse management team with various educational backgrounds and professional experiences[130][132][133]. - The company reported a total remuneration for the board of directors, supervisors, and senior management in 2024 is 5.7176 million yuan[137]. Investment and Financial Management - The total investment during the reporting period reached ¥1,044,345,991.68, a significant increase of 4,779.38% compared to ¥21,403,233.73 in the previous year[74]. - The company reported a net cash flow from investment activities was -¥1,109,461,774.79, a deterioration of 434.76% compared to -¥207,468,705.16 in 2023[68]. - The company has allocated 90,000,000 CNY for cash management from idle raised funds, with 7,975,220 CNY deposited in a special account[79]. - The company has committed to investing 119 million in various projects, with a focus on enhancing operational efficiency[82]. - The company plans to increase the cash management limit for idle raised funds, which may enhance liquidity and investment flexibility[121].

二、董事会会议审议情况 会议审议并通过了如下议案： 1、审议通过《关于制定舆情管理制度的议案》 为进一步完善湖北亨迪药业股份有限公司治理机构，提高公司应对各类舆情 的能力，根据《公司章程》的规定，结合公司实际情况，特制定《舆情管理制度》。 证券代码：301211 证券简称：亨迪药业 公告编号：2025-002 湖北亨迪药业股份有限公司 第二届董事会第十一次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届董事会第十一次会 议于 2025 年 2 月 21 日以电话及邮件方式送达至全体董事，本次会议于 2025 年 3 月 4 日以现场和通讯方式召开。本次会议应参会董事 8 人，实际参会董事 8 人， 公司监事、高级管理人员列席会议，本次会议由公司董事长程志刚主持。本次董 事会会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法规和 《公司章程》的有关规定，会议合法、有效。 三、备查文件 1、湖北亨迪药业股份有限公司第二届董事会第十一次会议决议。 特此公告。 湖北亨 ...

湖北亨迪药业股份有限公司 舆情管理制度 第一章 总则 第一条 为了提高湖北亨迪药业股份有限公司（下称"公司"） 应对各类舆情的能力，建立快速反应和应急处置机制，及时 妥善处理各类舆情对公司股价、商业信誉及正常经营活动造 成的影响，切实保护公司和投资者的利益，根据《深圳证券 交易所股票上市规则》及相关法律法规、规范性文件的规定 和《公司章程》，结合公司实际，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道、 不实报道； （二）社会上存在的已经或将给公司造成不良影响的传 闻或信息； 象或正常经营活动，使公司已经或可能遭受损失，已经或 可能造成公司股票及其衍生品交易价格变动的负面舆情。 （二）一般舆情：指除重大舆情之外的其他舆情。 第四条 本制度适用于公司及公司全资子公司。 第二章 舆情管理的组织机构及工作职责 第五条 公司应对各类舆情实行统一领导、统一组织、快速 反应、尊重事实、协同应对的工作机制。 第六条 公司成立应对舆情管理工作领导小组(以下简称"舆 情领导小组"），由公司董事长任组长，董事会秘书担任副 组长，成员由公司其他高级管理人员及相关职能部门负责人 组成。 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2024-054 湖北亨迪药业股份有限公司 第二届董事会第十次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届董事会第十次会议 于 2024 年 12 月 16 日以电话及邮件方式送达至全体董事，本次会议于 2024 年 12 月 23 日以现场和通讯方式召开。本次会议应参会董事 8 人，实际参会董事 8 人，公司监事、高级管理人员和保荐机构代表列席会议，本次会议由公司董事长 程志刚主持。本次董事会会议的召集、召开和表决程序符合《中华人民共和国公 司法》等法律法规和《公司章程》的有关规定，会议合法、有效。 二、董事会会议审议情况 会议审议并通过了如下议案： 本次申请延期的募投项目为"高端医药制剂国际化项目"，本次变更前原计 划达到预定可使用状态时间为 2024 年 12 月。为确保公司募投项目稳步实施，公 司根据目前募投项目的实际进展情况，经审慎研究论证，在不涉及项目实施主体、 实施地点、募集资金投资用途变更，项目实施 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2024-056 湖北亨迪药业股份有限公司 关于部分募集资金投资项目延期的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2021]3639 号文核准，亨迪药业向社会 公开发行人民币普通股（A 股）6,000.00 万股，发行价格为每股 25.80 元，募集资 金总额为人民币 1,548,000,000.00 元，扣除发行费用后募集资金净额为人民币 1,400,732,340.85 元。募集资金已于 2021 年 12 月 16 日划至公司指定账户。大信会 计师事务所（特殊普通合伙）于 2021 年 12 月 16 日对公司首次公开发行股票的 资金到位情况进行了审验，并出具了大信验字[2021]第 2-10059 号《验资报告》。 募集资金到账后，公司对募集资金进行了专户存储，并与保荐机构、存放募 集资金的银行签署了募集资金专户存储监管协议。 二、募集资金使用情况说明 公司募集资金投资项目已经 2020 年第一届董事会第二次会议、2020 年第 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2024-055 湖北亨迪药业股份有限公司 第二届监事会第十次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 1、湖北亨迪药业股份有限公司第二届监事会第十次会议决议。 二、监事会会议审议情况 会议审议并通过了如下议案： 1、《关于部分募集资金投资项目延期的议案》 本次申请延期的募投项目为"高端医药制剂国际化项目"，本次变更前原计 划达到预定可使用状态时间为 2024 年 12 月。为确保公司募投项目稳步实施，公 司根据目前募投项目的实际进展情况，经审慎研究论证，在不涉及项目实施主体、 实施地点、募集资金投资用途变更，项目实施的可行性未发生重大变化的情况下， 预计该募投项目达到可使用状态的日期将延长至 2026 年 12 月。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）刊载的《关于部 分募集资金投资项目延期的公告》。 表决结果：3 票同意、0 票反对、0 票弃权。该项议案获审议通过。 三、备查文件 湖北亨迪药业股份有限公司（以下简称"公司"） ...

国泰君安证券股份有限公司 关于湖北亨迪药业股份有限公司 部分募集资金投资项目延期的核查意见 国泰君安证券股份有限公司（以下简称"国泰君安"或"保荐机构"）作为 湖北亨迪药业股份有限公司（以下简称"亨迪药业"或"公司"）首次公开发行 股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深 圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》及《上市公司监管指引第 2 号——上市公司募集资金管理 和使用的监管要求》等相关规定，对亨迪药业部分募集资金投资项目延期事项进 行了审慎尽职调查，具体核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2021]3639 号文核准，亨迪药业向社会 公开发行人民币普通股（A 股）6,000.00 万股，发行价格为每股 25.80 元，募集资 金总额为人民币 1,548,000,000.00 元，扣除发行费用后募集资金净额为人民币 1,400,732,340.85 元。募集资金已于 2021 年 12 月 16 日划至公司指定 ...

2024年12月22日上午，湖北亨迪药业股份有限公司武汉研究院暨武汉亨迪原料药和制剂产品研发项目落 成典礼在武汉光谷南大健康产业园隆重举行。公司实际控制人新理益集团董事长刘益谦先生，亨迪药业 董监高，以及各界嘉宾一起见证了这一盛况。 亨迪药业董事长程志刚表示，亨迪药业一贯重视新技术投入和新品种研发，上市三年来持续加大研发投 入，累计投入1亿多元，成功开发了几十个品种，其中20个品规已经申报到国家药监局，目前已获得硫 酸阿托品原料药、醋酸阿比特龙原料药、布洛芬颗粒（0.2g）、布洛芬片（0.1g，0.2g）、托拉塞米片 （5mg，10mg）、米力农注射剂（5ml：5mg，10ml：10mg）等批文。公司坚持自主创新，申报并获得 多项国家发明专利，2023年公司获得"国家知识产权优势企业"荣誉称号，并连续4年获得中国医药 CDMO20强。未来武汉研究院将按照公司原料药制剂一体化的发展战略，致力打造一流科研中心，建设 绿色化学、连续流和手性合成等高端技术平台，高效研发原料药和制剂新品种，不断丰富产品管线，增 强公司在市场上的抗风险能力。同时借助武汉的区位优势和人才优势，吸引大量有创新力的高学历人 才，提升公司研发团 ...

湖北亨迪药业股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动的情况 证券代码：301211 证券简称：亨迪药业 公告编号：2024-053 湖北亨迪药业股份有限公司（以下简称"公司"） 股票于 2024 年 10 月 25 日、2024 年 10 月 28 日、2024 年 10 月 29 日，股票交易 连续 3 个交易日内日收盘价格涨幅偏离值累计超过 30%；根据深圳证 券交易所相关规定，属于股票交易异常波动的情况。 二、公司关注并核实情况的说明 针对公司股票异常波动情况，公司董事会通过电话及现场询问等 方式，对公司控股股东、实际控制人及持股 5%以上股东、公司全体 董事、监事及高级管理人员就相关问题进行了核实，现就相关情况说 明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道了与公司相关且市场关注度较 高的未公开重大信息。 3、公司目前的经营情况及内外部经营环境未发生重大变化。 4、公司、控股股东及实际控制人、持有 5%以上股份的股东不存 在关于公司应披 ...

Financial Performance - The company's revenue for Q3 2024 was ¥92,126,731.98, representing a decrease of 32.60% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥6,165,534.97, down 80.41% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was -¥1,511,042.32, a decline of 104.89% compared to the previous year[2]. - Total operating revenue for Q3 2024 was CNY 333,993,687.09, a decrease of 38.5% compared to CNY 542,445,746.24 in the same period last year[13]. - Net profit for Q3 2024 was CNY 74,661,546.28, a decline of 48.3% compared to CNY 144,514,979.02 in Q3 2023[14]. - The total comprehensive income attributable to the parent company for Q3 2024 is CNY 74,661,546.28, compared to CNY 144,514,979.02 in the same period last year, reflecting a decrease of approximately 48.3%[15]. - Basic and diluted earnings per share for Q3 2024 are both CNY 0.26, down from CNY 0.50 in the previous year, indicating a decline of 48%[15]. Assets and Liabilities - Total assets as of September 30, 2024, were ¥2,437,069,095.83, a decrease of 4.30% from the end of the previous year[2]. - The total assets as of Q3 2024 amounted to CNY 2,437,069,095.83, a decrease from CNY 2,546,570,975.79 at the end of the previous quarter[12]. - Current liabilities totaled CNY 128,361,400.85, down 26.7% from CNY 175,141,355.55 in the previous quarter[12]. - Non-current liabilities amounted to CNY 13,278,812.72, a decrease from CNY 14,744,778.82 in the previous quarter[12]. - The company’s total equity attributable to shareholders decreased by 2.60% to ¥2,295,428,882.26 compared to the end of the previous year[2]. - The total equity attributable to shareholders of the parent company was CNY 2,295,428,882.26, down from CNY 2,356,684,841.42 in the previous quarter[12]. Cash Flow - The company's cash flow from operating activities for the first nine months of 2024 was ¥48,958,629.78, down 41.01% year-on-year[8]. - Cash inflows from operating activities for Q3 2024 amount to CNY 358,511,330.00, a decrease of 29.2% from CNY 506,313,229.59 in Q3 2023[16]. - Net cash flow from operating activities is CNY 48,958,629.78, down 41% from CNY 82,988,321.06 in the same quarter last year[17]. - Cash outflows from investment activities total CNY 1,173,472,855.41, significantly higher than CNY 119,570,288.07 in Q3 2023, indicating a substantial increase in investment expenditures[17]. - The net cash flow from investment activities is -CNY 1,085,211,025.10, compared to -CNY 119,192,777.18 in the previous year, showing a worsening of investment cash flow[17]. - Cash and cash equivalents at the end of Q3 2024 stand at CNY 520,745,020.94, a decrease from CNY 1,729,396,597.93 at the end of Q3 2023, reflecting a decline of approximately 69.9%[17]. - The company reported a cash outflow of CNY 138,240,000.00 for financing activities, up from CNY 96,000,000.00 in the previous year, indicating increased financing costs[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,979, with the top 10 shareholders holding 38.25% of the shares[9]. - The largest shareholder, Shanghai Yongda Sheng Business Consulting Co., Ltd., holds 110,160,000 shares, accounting for 38.25% of the total[9]. - The top 10 shareholders include both natural persons and corporate entities, with significant stakes held by individuals related to the controlling shareholder[9]. - The company has not reported any changes in the number of preferred shareholders or any significant changes in restricted shares[9]. - The company has not engaged in any major financing or share lending activities during the reporting period[10]. Operational Metrics - The company experienced a 38.43% decline in total revenue for the first nine months of 2024, totaling ¥333,993,687.09, primarily due to reduced sales of ibuprofen[6]. - The basic earnings per share for Q3 2024 was ¥0.02, reflecting an 82.51% decrease compared to the same period last year[2]. - Research and development expenses for Q3 2024 were CNY 26,268,412.71, down 24.8% from CNY 34,932,093.15 in Q3 2023[13]. - The company reported a financial income of CNY 43,297,639.20, an increase from CNY 36,293,249.80 in the same period last year[14]. Changes in Financial Assets - The company reported a significant increase in trading financial assets, which rose by 747.61% to ¥1,096,806,208.33 due to the purchase of transferable large-denomination certificates of deposit[5]. - Trading financial assets increased significantly to ¥1,096,806,208.33 from ¥129,399,817.02[10]. - Accounts receivable rose to ¥65,278,637.33 from ¥52,444,817.42, indicating a growth of approximately 24.5%[10]. - Inventory decreased to ¥155,087,639.39 from ¥173,804,685.14, reflecting a decline of about 10.8%[10]. - Other receivables increased to ¥8,698,567.85 from ¥4,478,312.08, showing a growth of approximately 94.5%[10]. Audit and Compliance - The company has not undergone an audit for the Q3 2024 report[18].